T-Cell IL-6 Signaling Detection for Breast Cancer Relapse Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to elucidate the modulation of IL-6 signaling in breast cancer patients, particularly in those in remission, which is crucial for predicting relapse and managing immune responses.
Innovation Solution
Developed methods for detecting IL-6 activity in breast cancer patients by analyzing T cells, including CD4+ T cells, through the use of IL-6 pathway detection agents or probes, and quantifying IL-6 pathway proteins or mRNA expression sequences to predict relapse and treat IL-6 pathway-defective patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to detect IL-6 activity, then general IL-6 levels can be measured, but the specific modulation of IL-6 signaling in T cells of breast cancer patients cannot be elucidated
Solution Approach 1:
The patent segments the detection approach by specifically targeting T cell populations (CD4+ and CD8+ T cells) within the immune system to measure IL-6 signaling activity. This segmentation allows precise measurement of IL-6 activity in the specific cell type where signaling modulation occurs, rather than measuring general IL-6 levels in the entire immune system or serum.
Solution Approach 2:
The patent uses detection agents that specifically bind to IL-6 pathway proteins (such as STAT3 phosphorylation markers) as intermediaries to detect IL-6 signaling activity. These intermediaries enable the measurement of signaling modulation without directly measuring IL-6 cytokine levels, thus resolving the difficulty of detecting specific signaling changes.
2Reliability
If IL-6 activity is not specifically detected in T cells, then patient management remains general, but relapse prediction accuracy is insufficient
Solution Approach 1:
The patent performs preliminary detection of IL-6 signaling activity in T cells of breast cancer patients in remission. By detecting phosphorylation of STAT3 and other signaling molecules before relapse occurs, the method enables early prediction of relapse risk, improving reliability without requiring complex longitudinal monitoring.
Solution Approach 2:
The patent replaces complex clinical monitoring and mechanical assessment of patient status with a biochemical detection system that measures IL-6 pathway protein phosphorylation. This substitution simplifies the overall detection process while improving reliability by providing objective molecular markers of relapse risk.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods provide a means to predict breast cancer relapse and treat IL-6 pathway-defective patients by detecting IL-6 activity in T cells, thereby improving patient management and outcomes.
Implementation Method 1
contacting the biological sample with an IL-6 pathway detection agent capable of binding an IL-6 pathway protein, thereby forming a detectable complex
Implementation Method 2
contacting the biological sample with an IL-6 pathway probe capable of hybridizing an IL-6 pathway mRNA expression sequence, thereby forming a hybridization complex
Data Source
AI summary
The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.